Product Description
Mechanisms of Action: No Mechanism
Novel Mechanism: No
Modality: Unknown
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: None
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
10/28/2022 |
PubMed |
Wnt-5a induces the conversion of silent to functional synapses in the hippocampus. |
|
01/01/2022 |
PubMed |
The role of Wnt pathway antagonists in early-stage lung adenocarcinoma. |
|
08/05/2020 |
PubMed |
Wnt Signaling Pathway Dysregulation in the Aging Brain: Lessons From the Octodon degus. |